New eczema drug shows promise in Late-Stage trial
NCT ID NCT06277245
First seen Apr 29, 2026 · Last updated May 22, 2026 · Updated 2 times
Summary
This study tested an experimental drug called LNK01001 in 356 adults with moderate to severe atopic dermatitis (eczema) who had not responded well to standard creams or needed stronger treatment. Participants received either the drug or a placebo, and researchers measured improvements in skin rash and itching after 16 weeks. The goal was to see if LNK01001 can safely control the disease better than a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dermatological Hospital of Southern Medical University
Guangzhou, China
Conditions
Explore the condition pages connected to this study.